Clinical and pathogenetic rationale for the prevention and treatment of obesity.

Prof. O.M. Korzh.

Kharkiv Medical Academy of Postgraduate Education.

Numerous studies in recent years have identified obesity as a key cause of the development of type 2 diabetes, metabolic syndrome and cardiovascular diseases, which are among the most significant public health problems in most countries of the world. The high prevalence of obesity, which determines its comorbid nature, dictates the need to clarify the principles and options for not only treatment, but also prevention. In the process of active study, the multicomponent pathogenesis of obesity with the important role of various parts of the brain determines the feasibility of a combination of pharmacotherapy and intervention in lifestyle. In the pharmacotherapy of obesity, weight correction is an important component and can reduce the risk of cardiovascular complications, improve the quality of life and prognosis.

Key Words: obesity, metabolic syndrome, diabetes mellitus, cardiometabolic risk, microbiota, insulin resistance, treatment, prevention.


For citing:

1. Корж, А.Н. Клинико-патогенетическое обоснование профилактики и лечения ожирения // Східноєвропейський журнал внутрішньої та сімейної медицини. – 2020. – № 2. – С. 146-152. doi: 10.15407/internalmed2020.02.146.
2. Korzh OM. [Clinical and pathogenetic rationale for the prevention and treatment of obesity]. Shidnoevr. z. vnutr. simejnoi med. 2020;2:146-152. Russian. doi: 10.15407/internalmed2020.02.146.


1. Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians. Annals of Internal Medicine. 2005;142(7):525.
2. Lau D, Douketis J, Morrison K, Hramiak I, Sharma A, Ur E. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. Canadian Medical Association Journal. 2007;176(8):S1-S13.
3. Finucane M, Stevens G, Cowan M, Danaei G, Lin J, Paciorek C, Singh G, Gutierrez H, Lu Y, Bahalim A, Farzadfar F, Riley L, Ezzati M. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participants. The Lancet. 2011;377(9765):557-567.
4. J Am Coll Cardiol. 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. 2014; 63(25_PA): 2985-3023. doi:10.1016/j. jacc.2013.11.004.
5. Eur Heart J. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collabo- ration with the EASD. The Task Force on diabe- tes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) The European Society of Cardiology 2012. 2013;34:3035-3087.
6. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano F, Grassi G, Zanchetti A, Sega R. Metabolic Syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) Study. Hypertension. 2007;49(1):40-47.
7. Aguilera C, Labbé T, Busquets J, Venegas P, Neira C, Valenzuela Á. Obesidad: ¿Factor de riesgo o enfermedad?. Revista médica de Chile. 2019;147(4):470-474.
8. Misra A, Jayawardena R, Anoop S. Obesity in South Asia: Phenotype, Morbidities, and Mitigation. Current Obesity Reports. 2019;8(1):43-52.
9. Mohan V, Bodhini D. Mediators of insulin resistance & cardiometabolic risk: Newer insights. Indian Journal of Medical Research. 2018;148(2):127-129.
10. Schwartz M, Seeley R, Zeltser L, Drewnowski A, Ravussin E, Redman L, Leibel R. Obesity Pathogenesis: An Endocrine Society Scientific Statement. Endocrine Reviews. 2017;38(4):267-296.
11. McIntyre A. Burden of Illness Review of Obesity: Are the true costs realised?. Journal of the Royal Society of Health. 1998;118(2):76-84.
12. Ochner C, Tsai A, Kushner R, Wadden T. Treating obesity seriously: when recommendations for lifestyle change confront biological adaptations. The Lancet Diabetes & Endocrinology. 2015;3(4):232-234.
13. Sinclair P, Docherty N, le Roux C. Metabolic Effects of Bariatric Surgery. Clinical Chemistry. 2018;64(1):72-81.
14. Nainggolan L. Obesity as a “Brain Disease„; a Driver for New Therapies. 22nd European Congress on Obesity. 2015. Available from:
15. Luo C, Wang X, Huang H, Mao X, Zhou H, Liu Z. Effect of Metformin on Antipsychotic-Induced Metabolic Dysfunction: The Potential Role of Gut-Brain Axis. Frontiers in Pharmacology. 2019;10:371.
16. Bauer P, Hamr S, Duca F. Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota. Cellular and Molecular Life Sciences. 2015;73(4):737-755.
17. Petra A, Panagiotidou S, Hatziagelaki E, Stewart J, Conti P, Theoharides T. Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation. Clinical Therapeutics. 2015;37(5):984-995.
18. Hills R, Pontefract B, Mishcon H, Black C, Sutton S, Theberge C. Gut Microbiome: Profound Implications for Diet and Disease. Nutrients. 2019;11(7):1613.
19. Liu C, Wang C, Guan S, Liu H, Wu X, Zhang Z, Gu X, Zhang Y, Zhao Y, Tse L, Fang X. The Prevalence of Metabolically Healthy and Unhealthy Obesity according to Different Criteria. Obesity Facts. 2019;12(1):78-90.
20. Smith G, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. Journal of Clinical Investigation. 2019;129(10):3978-3989.
21. Longo M, Zatterale F, Naderi J, Parrillo L, Formisano P, Raciti G, Beguinot F, Miele C. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. International Journal of Molecular Sciences. 2019;20(9):2358.
22. Brøns C, Grunnet L. MECHANISMS IN ENDOCRINOLOGY: Skeletal muscle lipotoxicity in insulin resistance and type 2 diabetes: a causal mechanism or an innocent bystander? European Journal of Endocrinology. 2017;176(2):R67-R78.
23. Hwang I, Kim J. Two Faces of White Adipose Tissue with Heterogeneous Adipogenic Progenitors. Diabetes & Metabolism Journal. 2019;43(6):752-762.
24. Ye J, Kraegen T. Insulin resistance: central and peripheral mechanisms. The 2007 Stock Conference Report. Obesity Reviews. 2007;0(0):30-34.
25. Gummesson A, Nyman E, Knutsson M, Karpefors M. Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2017;19(9):1295-1305.
26. American Diabetes Association. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S51—S54. doi: 10.2337/ dc18-S005
27. Cook N, Appel L, Whelton P. Weight change and mortality: Long‐term results from the trials of hypertension prevention. The Journal of Clinical Hypertension. 2018;20(12):1666-1673.
28. Wang B, Cheng K. Hypothalamic AMPK as a Mediator of Hormonal Regulation of Energy Balance. International Journal of Molecular Sciences. 2018;19(11):3552.
29. Zhou Z, Tang Y, Jin X, Chen C, Lu Y, Liu L, Shen C. Metformin Inhibits Advanced Glycation End Products-Induced Inflammatory Response in Murine Macrophages Partly through AMPK Activation and RAGE/NFκB Pathway Suppression. Journal of Diabetes Research. 2016;2016:1-10.
30. Rodriguez J, Hiel S, Delzenne N. Metformin. Current Opinion in Clinical Nutrition & Metabolic Care. 2018;21(4):294-301.
31. Ha J, Yeom Y, Jang J, Kim Y, Im J, Kim I, Yang S. Anti-inflammatory Effects of Metformin on Neuro-inflammation and NLRP3 Inflammasome Activation in BV-2 Microglial Cells. Biomedical Science Letters. 2019;25(1):92-98.
32. Araujo J, Martel F. Sibutramine Effects on Central Mechanisms Regulating Energy Homeostasis. Current Neuropharmacology. 2012;10(1):49-52.
33. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, Bascil Tutuncu N, Guvener N. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, Obesity and Metabolism. 2002;4(1):49-55.
34. Chen K, Brychta R, Abdul Sater Z, Cassimatis T, Cero C, Fletcher L, Israni N, Johnson J, Lea H, Linderman J, O’Mara A, Zhu K, Cypess A. Opportunities and challenges in the therapeutic activation of human energy expenditure and thermogenesis to manage obesity. Journal of Biological Chemistry. 2019;295(7):1926-1942.
35. McGlashon J, Gorecki M, Kozlowski A, Thirnbeck C, Markan K, Leslie K, Kotas M, Potthoff M, Richerson G, Gillum M. Central Serotonergic Neurons Activate and Recruit Thermogenic Brown and Beige Fat and Regulate Glucose and Lipid Homeostasis. Cell Metabolism. 2015;21(5):692-705.